Jubilant reports JBI-802 platelet reductions in 12 patients
Key highlights
- Jubilant reported dose-dependent platelet-count reductions across 12 JBI-802 patients at SOHO 2026.
- JBI-802 remains in a company-sponsored Phase I/II ET/MPN study with a US market estimate of about USD 5 billion.
- Jubilant's proprietary novel-drug segment reported zero revenue and an Rs 18 crore EBITDA loss in H1 FY27.
- Jubilant plans an American Society of Hematology 2026 presentation and will explore licensing or external fund raising.
powered by IRIS

Jubilant Pharmova reported rapid, sustained and durable dose-dependent platelet-count reductions across 12 patients in its ongoing JBI-802 Phase I/II study at SOHO 2026, its first disclosed clinical dataset for the programme. Jubilant also said it would explore licensing or external fund raising for its proprietary novel-drug pipeline.
Know Jubilant Pharmova inside out
Results, valuation, peers and who's buying, in one view.
What did Jubilant report from JBI-802 at SOHO 2026?
Jubilant reported clinical activity in 12 patients in its ongoing JBI-802 Phase I/II study at the Society of Hematologic Oncology, or SOHO, 2026 Annual Meeting. The company said platelet counts declined in a dose-dependent manner and described the reductions as rapid, sustained and durable, with a manageable safety profile. This was the first clinical data presentation disclosed for JBI-802.
The presentation does not provide platelet-count values, dose levels, response rates, treatment duration, adverse-event frequencies or a comparator group for the 12 patients. That limits the quantitative conclusions available from the disclosure. JBI-802 remains in a company-sponsored Phase I/II trial, rather than a completed registrational study.
Which blood-cancer setting is Jubilant studying with JBI-802?
Jubilant is studying JBI-802 in essential thrombocythemia, or ET, and myeloproliferative neoplasm, or MPN, blood cancers through its company-sponsored Phase I/II trial. ET is a World Health Organization-defined MPN marked by elevated platelets and risks including thrombosis, bleeding, progression to myelofibrosis and leukaemia. Jubilant estimates about 150,000 ET patients in the US.
Jubilant says anagrelide and BESREMi are the only US Food and Drug Administration-approved medicines for ET, and that both carry boxed warnings. The company also says hydroxyurea is used off-label and has poor patient outcomes. It estimates the US total addressable market for the ET/MPN setting at about USD 5 billion.
What other JBI-802 cancer programmes does Jubilant list?
Jubilant lists non-small-cell lung cancer, or NSCLC, and post-MPN acute myeloid leukaemia, or AML, as two additional JBI-802 settings beyond ET/MPN. An investigator-led NSCLC trial has been initiated, while an investigator-led post-MPN AML study is under planning. These programmes are therefore at earlier or different development stages than the active company-sponsored blood-cancer trial.
For NSCLC, Jubilant says JBI-802 demonstrated clinical efficacy in two patients in a Phase I study and estimates a US total addressable market of about USD 3.1 billion. For post-MPN AML, it estimates the US market at about USD 0.8 billion and identifies progression from blood cancer to leukaemia as a serious complication. The presentation does not disclose a study timetable or patient count for the planned AML trial.
How does Jubilant plan to monetise JBI-802 and its novel-drug pipeline?
Jubilant says it will explore monetisation through licensing or external fund raising after presenting JBI-802's first clinical data at SOHO 2026. The statement identifies possible funding routes, but it does not disclose a licensee, financing amount, transaction valuation or timetable. No completed licensing transaction is reported in the presentation.
The company describes its proprietary novel-drug model as an in-house discovery engine intended to generate drug candidates at low cost and validate them through partnerships. It focuses on precision oral medicines for specific patients who are not responding to other therapies. The US Food and Drug Administration has granted orphan-drug designations to both JBI-802 and JBI-778.
JBI-778 is Jubilant's other lead programme and is in a company-sponsored first-in-human Phase I trial in India. Its listed targets include NSCLC with epidermal growth factor receptor, or EGFR, mutation, with a US market estimate of USD 2.0 billion, and high-grade glioma, or HGG, with an estimate of USD 1.7 billion. Jubilant also lists adenoid cystic carcinoma, or ACC, in head and neck cancer.
Got a follow-up? Ask IRIS
What is Jubilant spending on proprietary novel drugs?
Jubilant reported zero revenue from proprietary novel drugs in Q2 FY27 and H1 FY27 while continuing calibrated investment in JBI-802 and JBI-778. Segment earnings before interest, tax, depreciation and amortisation, or EBITDA, were a loss of Rs 10 crore in Q2 FY27, compared with a Rs 3 crore loss in Q2 FY26 and a Rs 8 crore loss in Q1 FY27.
The H1 FY27 EBITDA loss doubled to Rs 18 crore from Rs 9 crore in H1 FY26, while revenue was zero in both periods. The Q2 FY27 loss was Rs 2 crore higher than in Q1 FY27. These figures show that the proprietary novel-drug business was still funding development rather than generating medicine sales during the reported periods.
When is Jubilant expected to provide its next JBI-802 update?
Jubilant plans to present JBI-802 data at the American Society of Hematology Annual Meeting in 2026. This is the next disclosed clinical communication for the programme following the 12-patient SOHO 2026 report. The presentation does not state the number of patients, endpoints or safety details expected in that update.
The company-sponsored Phase I/II trial in ET/MPN remains underway, the investigator-led NSCLC trial has started, and the post-MPN AML study is under planning. Jubilant does not provide a regulatory-submission timetable for JBI-802. Its FY27-28 capital-allocation plan also prioritises committed capacity projects, funded first through internal accruals, grants and concessional loans.
Conclusion
Jubilant's first disclosed JBI-802 clinical report provides evidence of dose-dependent platelet-count reductions in 12 patients, while leaving key measures such as platelet values, dosing, response rates and adverse-event frequencies undisclosed. The company is simultaneously considering licensing or external fund raising, and its proprietary novel-drug segment recorded zero revenue with an Rs 18 crore EBITDA loss in H1 FY27.
The next disclosed event is Jubilant's planned American Society of Hematology presentation in 2026, which may provide additional detail on the ongoing Phase I/II study. Readers should also watch for whether the stated monetisation exploration produces a named partner, external funding terms or a clearer development plan for JBI-802 and JBI-778.


